Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book
(Sprache: Englisch)
In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the...
Leider schon ausverkauft
versandkostenfrei
Buch
667.68 €
333 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book “
Klappentext zu „Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book “
In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight.
The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.
In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight.
The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.
The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.
Inhaltsverzeichnis zu „Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book “
Anti-angiogenic Targets HER2/EGFR Targets Nuclear Receptors Hormone receptors Heme surface markers Other surface markers Bcr/abl Proteosome inhibitors PPAR gamma PARP Methylation Immune therapies Cytokines mTOR wynt/apc IGF, survival, PI3K, AKT
Autoren-Porträt
Editorial Board:
Bibliographische Angaben
- 2017, 1st ed., 1105 Seiten, mit farbigen Abbildungen, Maße: 19,3 x 27,9 cm, Englisch
- Herausgegeben:Marshall, John L.
- Verlag: Springer, New York
- ISBN-10: 1441907181
- ISBN-13: 9781441907189
Sprache:
Englisch
Kommentar zu "Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book"
0 Gebrauchte Artikel zu „Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Cancer Therapeutic Targets, m. 1 Buch, m. 1 E-Book".
Kommentar verfassen